Innovation-Driven Engagement with Regulators

Russ Altman, Stanford University
and Kim Branson, GSK
In conversation with: Jack Fuchs, Stanford University

Stanford professor Russ Altman acknowledges that startups often fear regulators, but insists that in the biotech space, the FDA is keen to work with companies to bring products to market and advise startups as part of an open dialogue. In the context of AI-driven drug development, GSK senior VP and Global Head of AI/ML Kim Branson adds, an evolving conversation between industry and government will lead to new ways of ensuring the safe delivery of cutting-edge therapies.